Pharmacopeial Specifications:
- Iron Content: 15–20%
- Identification: UV or HPLC
- Loss on Drying: ≤5%
- Related Substances: ≤1.0%
- Microbial Limits: Complies with pharmacopeial requirements
Applications in Pharmaceutical Formulation:
Used in oral formulations for the treatment of iron deficiency anemia, especially in patients with inflammatory bowel disease or intolerance to conventional iron salts. Typically formulated in capsules or tablets
Comments:
Ferric maltol enhances iron absorption via complexation with maltol, reducing free iron reactivity in the gut. It is well tolerated and associated with fewer GI side effects compared to ferrous salts, improving compliance in chronic therapy.
